This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Grant Agreement No. 875299

Project acronym: UNICOM
Project full title: Up-scaling the global univocal identification of medicines in the context of Digital Single Market strategy
Call identifier: H2020-SC1-DTH-2019

D9.4: IDMP Implementation guidance for pharmacy system suppliers (focus on patient medication list) - Common minimum data set

Version: 1.0
Status: Final
Dissemination Level¹: PU
Due date of deliverable: 30.11.2022
Actual submission date: 01.12.2022
Work Package: WP9: IDMP adoption by pharmacy system supplier
Lead partner for this deliverable: IDMP1
Partner(s) contributing: ZINDEX, VIDAL, SNOMED, IHD
Deliverable type²: R

Main author(s):
Ursula Tschorn IDMP1
Julie James IHD

Other author(s):
Leonora Grandia ZINDEX
Robert Van der Stichele IHD
Frédéric Doc VIDAL
Jane Millar, Monica Harry SNOMED

Resource consumption estimate: Person months

<table>
<thead>
<tr>
<th>Resource consumption estimate</th>
<th>Person months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ursula Tschorn (IDMP1)</td>
<td>0.5</td>
</tr>
<tr>
<td>Julie James (IHD)</td>
<td>0.25</td>
</tr>
</tbody>
</table>

¹ Dissemination level: PU: Public; CO: Confidential, only for members of the consortium (including the Commission Services); EU-RES: Classified Information: RESTREINT UE (Commission Decision 2005/444/EC); EU-CON: Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC); EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
² Type of the deliverable: R: Document, report; DEM: Demonstrator, pilot, prototype; DEC: Websites, patent fillings, videos, etc.; OTHER; ETHICS: Ethics requirement; ORDP: Open Research Data Pilot
Revision history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Changes made</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>25.07.2022</td>
<td>First draft</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
<tr>
<td></td>
<td>05.08.2022</td>
<td>the medication list minimal data list</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
<tr>
<td>0.2</td>
<td>7.9.2022</td>
<td>Comments Julie, integration of D1.6 Demonstrator and Helens story</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
<tr>
<td>0.3</td>
<td>23.9.2022</td>
<td>Version 0.3 Julie</td>
<td>Julie James (IHE)</td>
</tr>
<tr>
<td>0.4</td>
<td>21.10.2022</td>
<td>Version with comments from LG, FD and RVS</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
<tr>
<td>0.5</td>
<td>29.10.2022</td>
<td>Last edition for delivery</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
<tr>
<td>1.0</td>
<td>25.11.2022</td>
<td>Final version</td>
<td>Ursula Tschorn (IDMP1)</td>
</tr>
</tbody>
</table>

Statement of originality
This deliverable contains original unpublished work except where clearly indicated otherwise. Acknowledgement of previously published material and of the work of others has been made through appropriate citation, quotation or both.
Deliverable abstract

<table>
<thead>
<tr>
<th>Pharmacy systems almost all keep patient medication lists; this deliverable will provide guidance for pharmacy system providers on how IDMP can help pharmacists to use medication list information to provide high quality pharmaceutical care.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keywords: Pharmacy system provider, IDMP, Patient Medication List, Identifying medicinal products.</td>
</tr>
</tbody>
</table>

This document contains material, which is the copyright of the members of the UNICOM consortium listed above and may not be reproduced or copied without their permission.

The commercial use of any information contained in this document may require a license from the owner of that information.

This document reflects only the views of the authors, and the European Commission is not liable for any use that may be made of its contents. The information in this document is provided “as is”, without warranty of any kind, and accept no liability for loss or damage suffered by any person using this information.

© 2019-2023. The participants of the UNICOM project.
## TABLE OF CONTENTS

Revision history ......................................................................................................................... 2  
Deliverable abstract ..................................................................................................................... 3  
List of abbreviations .................................................................................................................. 6  
Executive summary ................................................................................................................... 7  
1 Introduction and Background ....................................................................................................... 8  
   1.1 Background – the Medication List .................................................................................. 8  
   1.2 Introduction to D9.4 ..................................................................................................... 8  
   1.3 Scope of the document ................................................................................................. 8  
      1.3.1 Audience .............................................................................................................. 8  
   1.4 Introducing “Helen’s Story” ......................................................................................... 9  
2 Minimum Attributes List (MAL) ................................................................................................. 9  
   2.1 MAL Table Overview .................................................................................................... 9  
   2.2 MAL Details .................................................................................................................. 15  
      2.2.1 Medicinal Product information .............................................................................. 15  
      2.2.2 Marketing authorisation information ..................................................................... 16  
      2.2.3 Packaged Medicinal Product information ............................................................. 16  
      2.2.4 Manufactured Item information .......................................................................... 17  
      2.2.5 Ingredient information ......................................................................................... 18  
      2.2.6 Pharmaceutical Product information ................................................................... 20  
   2.3 Using the data from the MAL: Helen in the Hospital ......................................................... 20  
   2.4 Using the data from the MAL: Helen in the Pharmacy ..................................................... 21  
3 Examples .................................................................................................................................. 22  
   3.1 Data model representation for Losec ............................................................................. 22  
   3.2 Alignment of Manufactured Item Quantity, Unit of Presentation and Pack Size ......................................................................................... 24  
   3.3 Expression of Strength .................................................................................................. 25  
   3.4 Medicinal Product with multiple pharmaceutical products ............................................. 27  
      3.4.1 Representation of Manufactured Items .................................................................. 28  
      3.4.2 Representation of Pharmaceutical Products .......................................................... 28  
4 Conclusions .............................................................................................................................. 29  

## LIST OF FIGURES

Figure 1 - Helen’s Electronic Medication List on her App ....................................................... 9  
Figure 2 - Helen in the Hospital ............................................................................................. 21  
Figure 3 - Helen in the Pharmacy .......................................................................................... 21
Figure 4 - Helen scans the Barcode of her Medication with her App
Figure 5 - Data model representation for Losec
Figure 6 - Simple package configurations
Figure 7 - Losec example, substance strength and substance reference strength
Figure 8 - Guidance to Presentation Strength, and Concentration Strength (1)
Figure 9 - Guidance to Presentation Strength, and Concentration Strength (2)
Figure 10 - Losec Strength Example
Figure 11 - Example of contraceptive medicinal product Qlaira
Figure 12 - Manufactured Item with multiple Pharmaceutical Products
Figure 13 - Product with multiple Pharmaceutical Products

LIST OF TABLES

Table 1: IDMP attributes and their relationship with the electronic Medication List
## List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Complete form</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>IDMP</td>
<td>Identification of Medicinal Products</td>
</tr>
<tr>
<td>MAL</td>
<td>Minimum Attributes List</td>
</tr>
<tr>
<td>MPID</td>
<td>Medicinal product identifier</td>
</tr>
<tr>
<td>NCA</td>
<td>National Competent Authority</td>
</tr>
<tr>
<td>PCID</td>
<td>Packaged Medicinal Product Identifier</td>
</tr>
<tr>
<td>PhPID</td>
<td>Pharmaceutical Product Identifier</td>
</tr>
<tr>
<td>RMS</td>
<td>Referential Management Service</td>
</tr>
<tr>
<td>UTI</td>
<td>Urinary Tract Infection</td>
</tr>
<tr>
<td>WP</td>
<td>Work Package</td>
</tr>
</tbody>
</table>
Executive summary

This delivery is focussed on the pharmacy system suppliers. Pharmacy systems almost all keep patient medication lists; this deliverable will provide guidance on how IDMP can help pharmacists to use IDMP data in the medication list information to provide high quality pharmaceutical care, both locally and in the cross-border context.
1 Introduction and Background

1.1 Background – the Medication List

For some time now, computerised medication systems (for prescribing, dispensing, administration and record of medicines for patients) have been repeatedly increasing treatment safety and decreasing the risk of harm caused by medication errors. With the advent of the implementation of the IDMP Standards, this process of increasing patient safety is extending to the ability to support cross border and global interoperability in medication information in eHealth.

However, the major challenge in many countries worldwide is and remains the merging of information from different systems (e.g., of general practitioners, specialists, or hospitals) and the creation of a uniform overview of the medicines of each patient. Hence the concept of the patient e-medication list to store all medication in use and relevant to a safety check.

For such an overview, information is necessary: on the one hand, on the prescribed medicines, on the other hand, on the medicines dispensed. Moreover, since doctors only document those medicines that they prescribe themselves, it is very difficult to obtain a standardised overview of all medicines for a patient. The risk for physicians of side effects and incompatibilities in the interplay of several medicines increases dramatically, especially when they do not have a full picture of all medications.

The medication list quickly conveys all medications the patient is currently taking, all past medications and the exact combination of medications being taken at the time of each patient visit.

1.2 Introduction to D9.4

Reference to Unicom delivery D5.7 Common minimum data set that needs to be implemented in the national NCA and eHealth solution.

An IDMP enabled medication list can be used to identify key facts about the patient and his medication, presenting opportunities to reduce the risks of errors of omission or commission. As a global standard, maintained by an international collaborative effort, IDMP offers a vendor-neutral resource for the pharmacy system to identify the patients’ medicines on his electronic medication list. Medicinal products’ attributes are listed as code and term following the Referential Management Service (RMS) lists, to allow international information exchange.

The pharmacies’ electronic medication list per patient is closely related to the patient’s medication in other eHealth applications. This document therefore refers to the document “D5.7 Common minimum data set that needs to be implemented in the national NCA and eHealth solution”, which describes the data elements needed for a medication list in eHealth solutions.

1.3 Scope of the document

This document intends to present a common minimum data element list that needs to be implemented in the pharmacy system using IDMP to make the bridge to other systems in the healthcare environment and specially to prescribing systems. Guidelines targeted at the pharmacy system provider will be focused to the minimal attributes needed to identify the patient’s medication list in a globally operable way.

1.3.1 Audience

This document is addressed to pharmacy system providers to facilitate the implementation of an IDMP based medication list in the pharmacy IT system.
1.4 Introducing “Helen’s Story”

To demonstrate how this can be understood in reality, “Helen’s Story” from the D1.6 Demonstrator is referenced in several places where it fits.

Helen has type 1 diabetes mellitus and has an app on her phone on which she collects her medical information. She is on a business trip to the Netherlands. She thinks that unfortunately she might have another Urinary Tract Infection (UTI).

She doesn’t know what product to take in the Netherlands but in the the UK, she would be given Monuril. This is also registered in her electronic medication list on her app. Since she is not feeling well she goes to the emergency department of a hospital in the Netherlands.

Figure 1 - Helens Electronic Medication List on her App

2 Minimum Attributes List (MAL)

The IDMP attributes listed in the table below are those needed for an IDMP based medication list stored in the pharmacy IT system. We consider the minimum set of information that the pharmacy system should have access to (whether it is “alone” or linked to an MPD) to ensure its ability to understand any cross-border prescription (Helen’s story see below). They are essentially limited to the identifier of a medicinal product (package identifier, active substance name, pharmaceutical form, and active strength). In the section following the table, each attribute is examined in more detail.

2.1 MAL Table Overview

The table below lists the Minimal Attributes with

- the chapter and reference in the EMA IDMP Implementation Guidance that describes the attribute
- the attribute name as used in the EMA IDMP Implementation Guidance
- a reference to an EMA data source if appropriate
- the preferred code system for all coded attributes
- the attribute name from the IDMP conceptual model (ISO 11615)
- the FHIR Medication Definition resource and element that should be used in communication of that attribute
- an example
# Table 1: IDMP attributes and their relationship with the electronic Medication List

<table>
<thead>
<tr>
<th>#</th>
<th>Attributes from EMA IG V2.1.1</th>
<th>EMA-SPOR database</th>
<th>Preferred coding system</th>
<th>Data Attribute</th>
<th>FHIR Path</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Medicinal Product</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1</td>
<td>Product Management Service Identifier (PMS ID)</td>
<td></td>
<td></td>
<td>Medicinal Product Code</td>
<td>MedicinalProductDefinition.id</td>
<td>000005005; 00001234; 0000567; 0000174</td>
</tr>
<tr>
<td>1.2</td>
<td>Medicinal Product Identifier (MPID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5; 1.6</td>
<td>Authorised Pharmaceutical Form</td>
<td>RMS</td>
<td>EDQM</td>
<td>Pharmaceutical Dose Form; Combined pharmaceutical dose form</td>
<td>MedicinalProductDefinition.extension.authorisedDoseForm; MedicinalProductDefinition.combinedPharmaceuticalDoseForm</td>
<td>solution for injection in pre-filled syringe, tablet, cream, powder and solvent for solution for injection</td>
</tr>
<tr>
<td>1.14</td>
<td>Medicinal Product Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.14.1</td>
<td>Full name</td>
<td></td>
<td></td>
<td>Brand Name of the Medicinal Product</td>
<td>MedicinalProductDefinition.name.productName</td>
<td>Diclofenac PharmaABC 32 Filmtabletten</td>
</tr>
<tr>
<td>2.</td>
<td>Marketing authorisation information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.8</td>
<td>Marketing Authorisation Holder</td>
<td>OMS (LOC-ID)</td>
<td>SPOR-OMS</td>
<td>Marketing Authorisation Holder of the medicinal product</td>
<td>RegulatedAuthorization.holder</td>
<td>ORG-100002271 STADApharm GmbH Germany LOC-100002468 Bad Vilbel</td>
</tr>
<tr>
<td>4.</td>
<td>Packaged Medicinal Product</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1</td>
<td>Packaged medicinal product Identifier (PCID)</td>
<td></td>
<td></td>
<td>Medicinal Product Code</td>
<td>PackagedProductDefinition.id</td>
<td>SE-100001745-00040001-0001; EU-100000396-00020080-0001</td>
</tr>
<tr>
<td>4.3</td>
<td>Pack size**</td>
<td>EDQM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.8</td>
<td>Package item (container)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.8.1</td>
<td>Package item (container) type</td>
<td>RMS</td>
<td>EDQM</td>
<td>Medicinal Product Package</td>
<td>PackagedProductDefinition.packageItem.type</td>
<td>Bottle Blister Box Vial Blister Sleeve Pre-filled Syringe</td>
</tr>
<tr>
<td>4.8.5</td>
<td>Package item (container) quantity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 4.11.1 Unit of Presentation

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 4.11.1.1 Unit of Presentation

- **RMS**: actuation, patch, tablet

**Units of presentation:**
- actuation
- patch
- tablet

**Example:**
- In case of tablets/capsules the number of tablet/capsules in the immediate is specified: 28 tablets, 24 capsules
- In case of formulations contained in a vial (e.g. liquids) the total quantity/volume should be expressed: 5 mg, 2 mL
- In case of lyophilised formulations contained in a vial (e.g. powder), the total quantity/volume should be expressed: 1 vial

### 4.11.2 Manufactured Item Quantity

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 4.11.2.1 Manufactured Item Quantity

- **RMS**: 28 tablets, 5 ml, 1 vial

**Package size:**

**Example:**
- Medicinal Product ABC 20mg/ml powder and solvent for solution for injection (combined pharmaceutical form) in a vial will contain two types of manufactured items with the following dose forms:
  - Powder for solution for injection
  - Solvent for Solution for injection

### 4.11.3 Manufactured Dose Form

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 4.11.3.1 Manufactured Dose Form

- **RMS**: Tablet

**Pharmaceutical Dose Form**

**Example 1:**
- Medicinal Product ABC 20mg/ml powder and solvent for solution for injection (combined pharmaceutical form) in a vial will contain two types of manufactured items with the following dose forms:
  - Powder for solution for injection
  - Solvent for Solution for injection

**Example 2:**
- Medicinal Product DEF 500 mg tablets contain a single type of manufactured item with the following manufactured dose form:
  - Tablet

### 5 Ingredient

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 5.1 Ingredient role

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ingredient role:**
- Active

**Example:**
- Active Ingredient

### 5.5 Substance

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 5.5.1 Substance

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Active Ingredient**
- diclofenac sodium; diclofenac diethylamine ; diclofenac

#### 5.5.2 Strength (Presentation single value or low limit)

<table>
<thead>
<tr>
<th>Value</th>
<th>RMS</th>
<th>EDQM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDQM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Strength of the Medicinal Product**
- Tablet 500 mg
| 5.5.2.3.2 | Strength (Concentration single value or low limit) | RMS | EDQM | Ingredient.substance.strength.concentration | Strength presentation single value or low limit: numerator 500 mg, denominator 1 tablet. Strength presentation high limit: <blank>. Powder for solution for injection 88-90 mg in a vial. Strength presentation single value or low limit: numerator 88 mg, denominator 1 vial. Strength presentation high limit: 90 mg, denominator 1 vial. |
| 5.5.2.3.3 | Reference Strength (Presentation single value or low limit) | RMS | EDQM | Ingredient.substance.strength.referenceStrength.strength | Solution for injection 20 mg/ml. Strength concentration single value or low limit: numerator 20 mg, denominator 1 ml. Strength concentration high limit: <blank>. Powder and solvent for solution for injection 95-100 mg/ml. Strength concentration single value or low limit: numerator 95 mg, denominator 1 ml. Strength concentration high limit: 100 mg, denominator 1 ml. |
| 5.5.3.1 | Reference Substance | SMS | SPOR-SMS | Active Ingredient | Ingredient.substance.strength.referenceStrength.substance |
| 5.5.3.3.2 | Reference Strength (Presentation single value or low limit) | RMS | EDQM | Strength of the Medicinal Product | Ingredient.substance.strength.referenceStrength.strength |
| 5.5.3.4.2 | Reference Strength (Concentration single value or low limit) | RMS | EDQM | Ingredient.substance.strength.referenceStrength.strength |

### 6. Pharmaceutical Product Identifier (PhPID)

- Medicinal Product Code

Note: This version of the guidance does not report information on additional identifiers such as the Pharmaceutical Product Identifier (PhPID). Further details on the related definitions and defining elements will be available at later stage as it requires further discussions prior the implementation.
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>RMS</th>
<th>EDQM</th>
<th>Adm. Product Type</th>
<th>Code</th>
<th>Presentation</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.2</td>
<td>Administrable Dose Form</td>
<td>RMS</td>
<td>EDQM</td>
<td>Pharmaceutical Dose Form</td>
<td>AdministrableProductDefinition.administrableDoseForm</td>
<td>Solution for injection; Capsule, hard</td>
<td></td>
</tr>
<tr>
<td>6.3</td>
<td>Unit of Presentation</td>
<td>RMS</td>
<td>EDQM</td>
<td>Unit of Presentation</td>
<td>AdministrableProductDefinition.unitOfPresentation</td>
<td>Actuation; Drop; Puff</td>
<td></td>
</tr>
<tr>
<td>6.6</td>
<td>Route of Administration</td>
<td>RMS</td>
<td>EDQM</td>
<td>Route of Administration</td>
<td>AdministrableProductDefinition.routeOfAdministration.code</td>
<td>Auricular use; Cutaneous use</td>
<td></td>
</tr>
</tbody>
</table>
2.2   MAL Details

Below you can find more detailed information on the data elements listed.

2.2.1   Medicinal Product information

Product Management Service Identifier (PMS ID)

This is required as a specific and unique identifier of medicinal products related to EMA and regulatory authorities. It should be provided when it is available. The PMS ID will be automatically generated following a successful initial submission of the medicinal product information in the EMA PMS system.

In PMS, each individual medicinal product entry is assigned a single and unique PMS identifier (PMS ID) that remains unchanged through the lifecycle of the medicinal product. The PMS ID is a supplementary stable ID to any existing authorisation number or equivalent identifier as assigned by an authorising body.

The PMS ID is only composed by digits.

Example of PMS IDs would be: 00005005; 00001234; 00000567; 00000174.

Note: While the format of the identifier is confirmed, the number of digits may vary based on the amount of medicinal product entries performed in PMS. These examples are illustrative only.

Medicinal Product Identifier (MPID)

This is required as a specific national identifier of medicinal products. It should be provided when it is available.

MPID will be assigned to each authorised medicinal product; it is a supplementary ID to any existing authorisation number or equivalent identifier as assigned by an authorising body in a region.

The MPID is defined by the following segments:

- country code segment (ISO 3166-1 alpha-2 code elements)
- marketing authorisation holder (i.e. location ID) code segment
- medicinal product code segment (i.e. unique medicinal product ID)

Any change of the values related to these three code segments will result in the assignment of a new MPID.

This attribute is automatically generated and maintained by the PMS system.

Authorised Pharmaceutical Form

The pharmaceutical form might be authorised or submitted for authorisation as follows:

- Combined pharmaceutical form: when two or more manufactured dose forms that are intended to be combined to create a single administrable dose form. In this case the RMS list “Combined pharmaceutical form” is used.

  Example: powder and solvent for solution for injection

- Pharmaceutical dose form: when the authorised dose form does not need of combination prior administration into the patient. In this case the RMS list “Pharmaceutical dose form” is used.

  Examples: tablet, capsule, solution for injection

- Combined terms: in special cases (e.g. identical products which may be distinguished only by reference to the container), the information about the immediate container can be included in the authorised pharmaceutical form. In this case the RMS list “Combined term” is used.

  Example: solution for injection in pre-filled syringe

- Combined Package: medicinal products may consist of two pharmaceutical products that correspond with two different administrable dose forms (e.g. hard capsule and cream) that form
individual entities which do not need combining for administering to the patient. In this case the RMS list “Combination Package” is used.

Example: Cream + vaginal tablet

“Authorised Pharmaceutical Form” should be preferred over “manufactured dose form” and “administrable dose form” when describing a Medicinal Product

**Full name**

The full medicinal product name as indicated in Section 1: Name of the Medicinal Product of the corresponding SmPC or other regulatory document is specified, in line with the local language of the country where the product is authorised.

- Full name, country and splitting of the name in parts must be repeated as per applicable languages in multi-language countries (e.g. Belgium)
- Marketing authorisation holder may submit translations of the name in English on an optional basis.
- This is a repeatable field

### 2.2.2 Marketing authorisation information

**Marketing Authorisation Holder**

The Marketing authorisation holder is specified using the location identifier (LOC ID) linked to the organisation (ORG-ID) as listed in EMA’s Organisation Management System (OMS).

In the medication list, only the name of the organisation is required.

### 2.2.3 Packaged Medicinal Product information

**Packaged medicinal product Identifier (PCID)**

For each Packaged Medicinal Product, a unique PCID is assigned by the PMS system based on the data submitted.

It is supplementary to any existing authorisation/approval number at package level assigned by the Commission or national competent authorities.

In the medication list, it is required as a specific national identifier of medicinal products. It should be provided when it is available and should be preferred over MPID and PMSID. Also international identifiers such as GS1 identifiers may be used.

**Pack size**

This attribute is required to describe complex packaging medicines. It is provided when a medicinal product presents more than 2 different units of presentation.

**Example 1:** 28 tablets and 1 tube (cream) – In this case the pack size field is repeated including quantity and unit of presentation for tablets and quantity and unit of presentation (tube) for the cream.

For each Packaged Medicinal Product, the pack size defined as the total number of units of the manufactured item or package item and represented per unit of presentation is provided.

For medicinal products with multiple pharmaceutical products (e.g. tablet and cream) the pack size is differentiated and repeated by manufactured item/package item.

For medicinal products in solid dosage forms with multiple pharmaceutical products that present the same unit of presentation (e.g. contraceptive tablets of different colours and formulation), the pack size is accounted as the total number of tablets.

**Example 2:**
- 5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest
- 17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest
- 2 dark red tablets each containing 1 mg estradiol valerate
2 white tablets do not contain active substance
In this case the pack size field is completed with the following value: 26 tablets

For liquid formulations that needs of combinations (e.g. powder and solvent for solution for injection), the unit of presentation is differentiated, and this data field is repeated per manufactured item.

Example 3:
powder (25 mg vial) and solvent (1 ml pre-filled syringe). In this case the pack size field is repeated including quantity and unit of presentation for the powder (vial) and quantity and unit of presentation (syringe) for the solvent.
Value: 1 vial + 1 pre-filled syringe

The applicable numeric value(s) and unit of presentation is selected from the term ID as listed in the “Unit of Presentation” (RMS) list.

Example 4:
28 film coated tablets containing:
2 dark yellow tablets each containing 3 mg estradiol valerate

Package item (container)
- Package item (container) type
This attribute is required to describe complex packaging medicines. It should be associated with “Package item (container) quantity”. In that sense it can be repeatable to indicate the structure of packaging (example: ‘-Box; ‘-Pre-filled syringe; ‘-Vial). It is listed as term ID as listed in the “Packaging (RMS) list”.

- Package item (container) quantity
This attribute is required to describe complex packaging medicines. It must be used to complement the information of the “Package item (container) type” to describe their content. (Example: Package item (container) type: Blister / Package item (container) quantity`: 2).

Example 5:
Medicinal product B comprises combined pharmaceutical form powder (40 micrograms) and solvent (1 ml) for solution for injection. This package example consists of two vials with solvent and two vials with powder, all vials packaged in a single carton box.
- Carton x 1
  - Vial (solvent) x 2
  - Vial (powder) x 2

2.2.4 Manufactured Item information

Unit of Presentation
For the most of cases “unit of presentation” will be the same for “manufactured item” and “pharmaceutical product”. However, in some cases they can be different (e.g., eye drop product - for “manufactured Item” - “Container”, for pharmaceutical product: “drop”.
Pharmaceutical product Unit of presentation should be preferred. Ideally the 2 attributes should be available presented, however on the impossibility to provide both, it should be clearly specified which attribute is being provided.
When there is a difference between them, “Pharmaceutical product” “Unit of presentation” should be preferred over “Manufactured item” “Unit of presentation” to be given in the MAL.

Manufactured Item Quantity
The quantity (or count number) of the manufactured item in the medicinal product package, is specified as a value and units as per section 6.5 of the SmPC.
For solid dose forms and other items measured by counting, discrete countable entities, the unit for quantity is “unit” and the “unit of presentation” is the item counted within the immediate container.

For formulations contained in a vial, the unit for quantity is volume/quantity and the “unit of presentation” is the discrete countable entity, in which a pharmaceutical product or manufactured item is presented.

**Example 6:**
- In case of tablets/capsules the number of tablet/capsules is specified: 28 tablets, 24 capsules
- In case of formulations contained in a vial (e.g. liquids) the total quantity/volume is expressed: 5 mg, 2 mL
- In case of lyophilised formulations contained in a vial (e.g. powder), the total quantity/volume is expressed: 1 vial

**Manufactured Dose Form**

See comments on “Authorised Pharmaceutical Form”.

- The manufactured dose form is described with the authorised pharmaceutical form(s) in section 3. Pharmaceutical Form of the SmPC or other regulatory document (description prior to any transformation into the final form administered to the patient).
- The required authorised pharmaceutical form is specified as a term ID as listed in the “Pharmaceutical Dose Form” (RMS) list.
- If multiple values apply to the same medicinal product, then multiple manufactured items are listed.
- Deprecated (i.e. non-current) dose form terms may be referenced.

This is a repeatable field.

#### 2.2.5 Ingredient information

**Ingredient role**

The ingredient role is provided to indicate the role of the medicinal product ingredients (active, excipient, advent, etc.), the active ingredients are mandatory, and other as excipients are optional. However, some ingredients (excipients) with potential allergenic are indicated to be provided (colourings like fuchsin and malachite green etc.).

The role of the ingredient as part of the manufactured item/pharmaceutical product is specified as a term ID.

The applicable value(s) is selected from the term ID as listed in the “Ingredient Role” (RMS) list.

**Substance**

It describes the name and code of the exact ingredient of a medicinal product and is mandatory. It is identified with the “SPOR – Substances Management Services” (SMS).

The Substances contained within the medicinal product (either part of the pharmaceutical product(s) or the manufactured item(s)) is specified.

Each pharmaceutical product or Manufactured Item lists information on:

- active ingredient(s);
- excipient(s);
- in some instances, pharmaceutical product can also contain adjuvants.

The Substance(s) contained in pharmaceutical product or Manufactured Item are specified as a term ID.

The selected SMS ID refers to a particular substance, and the preferred term (PT) for that substance will always be the name displayed in PMS. In many cases, alternate names are stored for substances and the SMS ID can be found by using any of the names associated with a substance.

Note: every pharmaceutical product has at least one active ingredient. If a pharmaceutical product contains no active ingredient, one of the excipients is labelled as the active ingredient (example: water...
for injection as a solvent in a separate container, glucose solution 5%, NaCl solution 0.9%; contraceptive tablets containing only lactose).

**Strength (quantitative composition)**

**Strength (Presentation single value or low limit) / Strength (Concentration single value or low limit)**

It describes the strength of “moiety + modifier” (presentation or concentration) and it is referent to “substance”. All strengths have unit and a value for the nominator, and a unit and a value for the denominator. It is important to have value sets for these concepts (unit of nominator strength, unit of denominator strength). It should be complementary information over “Reference strength”.

The strength (quantitative composition) of the substances (including active substances, ingredients, adjuvant as applicable) are specified in this field with a numerator and denominator.

When the strength is expressed as a range, the lower limit for the quantity of the substance in the unit of presentation is specified in this field.

When the strength is not expressed as a range, the quantity of the substance is specified in this low limit field.

The numerator are expressed with a unit (numeric value) and a unit of measurement (e.g. mg).

The denominator are expressed with a unit (numeric value) and a unit of presentation (e.g. tablet, actuation).

The unit for the numerator is specified as a value and a Term ID as listed in the “Units of Measurement” RMS list. The units for the denominator are specified as a value and a Term ID as listed in the “Units of Presentation” RMS list.

**Example 7**

**Tablet 500 mg**

**Strength presentation single value or low limit: numerator 500 mg, denominator 1 tablet**

**Strength presentation high limit: <blank>**

**Powder for solution for injection 88-90 mg in a vial**

**Strength presentation single value or low limit: numerator 88 mg, denominator 1 vial**

**Strength presentation high limit: 90 mg, denominator 1 vial**

**Reference Strength**

**Reference Substance**

The reference substance of the active substance(s) contained in pharmaceutical product or Manufactured Item, as expressed in section 2. Qualitative and Quantitative Composition of the corresponding SmPC is specified.

The reference substance is provided for active substances only. It describes the active ingredient without the modifier (moiety). It is provided to support the description of “Reference strength” and useful for generic prescriptions.

**Reference Strength (Presentation single value or low limit) / Reference Strength (Concentration single value or low limit)**

The reference strength (quantitative composition) of the active substances is specified in this field with a numerator and denominator.

When the reference strength is expressed as a range, the lower limit for the quantity of the reference substance in the unit of presentation is specified in this field.
When the reference strength is not expressed as a range, the quantity of the reference substance is specified in this field.

The numerator is expressed with a unit of numeric value and a unit of measurement (e.g. mg).

The denominator is expressed with a unit of numeric value and a unit of presentation (e.g. tablet).

The reference strength is provided for active substances only.

The units for the numerator are specified as a value and a Term ID as listed in the “Units of Measurement” RMS list.

The units for the denominator are specified as a value and a Term ID as listed in the “Units of Presentation” RMS list. "Strength (Presentation and Concentration).

This attribute is the most used on prescriptions. It considers only the strength of the moiety. This information will be consumed by the eHealth services and should be considered preferred over “strength”.

### 2.2.6 Pharmaceutical Product information

#### Pharmaceutical Product identifier (PhPID)

It is required as a specific identifier of the pharmaceutical products (same substance, strength, administrable dose form and unit and value of measurement). IDMP requires the substance with the role of precise active ingredient substance (PAI) to be mentioned by moiety + modifier (if there is one).

#### Administrable Dose Form

See comments on “Authorised Pharmaceutical Form”

#### Unit of Presentation

See comments on “Manufactured Item / Unit of Presentation”.

#### Route of Administration

For most of the medicinal products there is only one possible “Route of Administration” (RoA), however, in some cases, there are many possible RoA, in that case the intended prescribed RoA should be specified over all possible RoA for a specific medicine.

The route of administration of the pharmaceutical form is specified in accordance with Section 4.2. Posology and method of administration of the SmPC as Term ID.

Administration route section describes the route(s) of administration i.e. the path by which the medicinal product (described as technical concept of a "pharmaceutical product") is taken into or makes contact with the body.

The applicable value(s) are selected from the term ID as listed in the “Routes and Methods of Administration” (RMS) list.

### 2.3 Using the data from the MAL: Helen in the Hospital

At the hospital emergency department Helen shows her Medication app which includes her International Patient Summary (IPS). In this case the IPS shows, next to the brand name, strength and dose form, the global PhPID (L4) of the current medication that is prescribed to Helen in her home country e.g. Humalog Mix 50 daily (global PhPID: 0x073AF2E5B92AE19E8B67635AFFB3D6CA) for her Diabetes mellitus type I. The IPS also contains her previous prescribed medicinal products and therefore shows the global PhPID (L4) for Monuril® fosfomycin (as trometamol) 3g per sachet granules for oral solution (global PhPID: 0xE857DA811B4A6F3BD57810C45D2EA1ED).

Disclaimer: the MPID, PCID and GTIN shown here are all ‘dummy data’ but as close to reality as possible.
2.4 Using the data from the MAL: Helen in the Pharmacy

Reference to Unicom delivery D1.6 Demonstrator “Helens Story”

The pharmacist retrieves, from the national MPD, a list of equivalent national medicinal products (Brand name, strength, and dose form) having the same PhPID Fosfomycin 3g oral solution (Monuril) as the product that Helen has in her own country. The pharmacist chooses the best option considering the information in Helen’s IPS regarding allergies of the retrieved products. The pharmacist then gives Helen her medication.
Helen scans the barcode on the medicinal product she received to include it in the medication list in her app.

Figure 4 - Helen scans the Barcode of her Medication with her App

3 Examples

Reference to Product Management Service (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe

Chapter 8 – Practical examples, Version 2.1.1., retrieved 7.8.2022

3.1 Data model representation for Losec

In the IDMP data model below, all the data elements listed in this document are tagged with a green marker.
Figure 5 - Data model representation for Losec
3.2 Alignment of Manufactured Item Quantity, Unit of Presentation and Pack Size

This section provides guidance with examples on how encoding medicinal product packaging information, together with the relationship between Pack Size, Package Item (container) quantity, and unit of presentation and quantity of the manufactured item is delivered.

For pharmacy system provider it is important to know how to record values for Pack size, Package Item (immediate container) Quantity, Manufactured Item Quantity and Unit of Presentation including multi-packs and multi-dose packs.

The example below depicts simple package configurations for solid dosage forms, comprising an outer box (secondary packaging) and blisters (primary/immediate packaging). These are very common.
Figure 6 - Simple package configurations

In the example above, the pack of 7 tablets can only contain 1 blister of 7 tablets. In this case, the Manufactured Item Quantity = 7 units, and the Package Item (Container) Quantity = 1.

Multiplying the Manufactured Item and Package Item (Container) quantities should equal the quantity encoded in the Pack Size of the Package Medicinal Product. However, the 14-tablet pack can contain either 2 blisters of 7 or 1 blister of 14 tablets. When this is the case, the fields ‘Manufactured Item Quantity’ and ‘Package item (Container) Quantity’ are left blank, and the number of tablets (14 in this case) is encoded in the ‘Pack size’ at ‘Packaged Medicinal Product.

3.3 Expression of Strength

This section provides guidance on how information on strength, and reference strength of active ingredients present in pharmaceutical products and manufactured items of medicinal products is defined.

Currently there are different practices across the EU when it comes to expressing the strength in the labelling of medicinal products, especially for parenteral preparations, products with a multidose presentation and older products if both types to express the strength are included in the SmPC. These split views are well acknowledged by all the stakeholders and must be considered when interpreting this information.

In the Losec example, both substance strength and substance reference strength can be found in the document for the active ingredient and are listed. The strength is listed for the excipient (sucrose).
Losec example, substance strength and substance reference strength

To give structure to the different approaches of expressing strength, a set of patterns has been developed. The patterns show how the Manufactured Item (MI) and the Pharmaceutical Product (PhP) are expressed for a particular type of product. Products can then be matched to the appropriate pattern which then can be used to group medicinal products in generic groups based on strength comparison.

The following reference table provides the necessary guidance to select between Presentation Strength, and Concentration Strength.

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Type of product</th>
<th>Examples</th>
<th>Manufactured Item Unit of Present</th>
<th>Pharmaceutical Product Unit of Present</th>
<th>Strength by Presentation</th>
<th>Strength by Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Solid, countable</td>
<td>Tablets, capsules, suppositories</td>
<td>Basic dose form related to the pharmaceutical form of the MI (tablet, capsule, etc.)</td>
<td>Basic dose form related to the pharmaceutical form of the PhP Prod (tablet, capsule etc.)</td>
<td>Mandatory</td>
<td>Empty</td>
</tr>
<tr>
<td>1b</td>
<td>Solid dose forms in &quot;container&quot;</td>
<td>Powder or granules in sachet, ampoules, vials, Spincap, Roscap – the whole content of the capsule is delivered to the patient via one or more actuations</td>
<td>Container (vial, sachet, etc.)</td>
<td>Container (vial, sachet, etc.) – not always informative depending on the dosing instructions</td>
<td>Mandatory</td>
<td>Empty</td>
</tr>
<tr>
<td>1c</td>
<td>Metered dose delivered by a metered actuation – dose cannot be adjusted</td>
<td>Dry-powder inhalers (DPI) pressuredmetered-dose inhalers (pMDI), nasal sprays</td>
<td>Actuation (inhaier)</td>
<td>Actuation (inhaier, etc.)</td>
<td>Mandatory</td>
<td>Empty</td>
</tr>
<tr>
<td>2a</td>
<td>Products enclosed in a &quot;presentation&quot;, where the total amount per presentation is clinically relevant</td>
<td>Unit dose solutions, parenteral liquid, unit dose nebulizer solutions NOT partial use preparations</td>
<td>Container (vial, etc.)</td>
<td>Container (vial, etc.)</td>
<td>Expressible per total volume of the presentation (not per unit of presentation). This makes calculations easier</td>
<td>Mandatory (QD)</td>
</tr>
</tbody>
</table>
In the following example the Losec strength fits with the Pattern 1a (Solid, countable). In this case, only the Presentation Strength is given for both manufactured Item and Pharmaceutical Products.

**Figure 9 - Guidance to Presentation Strength, and Concentration Strength (2)**

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Type of product</th>
<th>Examples</th>
<th>Manufact. Item Unit of Present.</th>
<th>Pharm. Prod. Unit of Present</th>
<th>Strength by Presentation</th>
<th>Strength by Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>2b</td>
<td>Products enclosed in a &quot;presentation&quot;, where the concentration is clinically relevant rather than the total amount in the presentation</td>
<td>Multi-dose syringe, Partial dose syringe, infusion bags, Multidose vial</td>
<td>Container (bottle, etc.)</td>
<td>N/A since it is the concentration that is relevant</td>
<td>Conditional</td>
<td>Mandatory</td>
</tr>
<tr>
<td>3a</td>
<td>Continuous presentation (dosing is individual/not accurate and the total volume in the container is of less importance for dosing purposes)</td>
<td>Bulk powders/granules, semi-solids “bulk” liquids (e.g., eye drops)</td>
<td>Not useful clinically</td>
<td>N/A since it is the concentration that is relevant</td>
<td>–</td>
<td>Conditional</td>
</tr>
<tr>
<td>3b</td>
<td>Products enclosed in a &quot;presentation&quot;, where the dose has a delivery rate</td>
<td>Transdermal patches</td>
<td>Patch</td>
<td>N/A since it is the concentration that is relevant</td>
<td>Conditional</td>
<td>Mandatory – as a delivery rate over time</td>
</tr>
</tbody>
</table>

**Figure 10 - Losec Strength Example**

**3.4 Medicinal Product with multiple pharmaceutical products**

A pharmaceutical product can be defined as the qualitative and quantitative composition of a medicinal product in the authorised dose form approved for administration. There are several instances where medicinal products may contain multiple pharmaceutical products characterised by different strengths, pharmaceutical forms, or substances.
To illustrate this concept, the example of contraceptive medicinal product Qlaira is used. This medicinal product is composed of several different manufactured items which are not transformed, giving several different pharmaceutical products, including a placebo. These pharmaceutical products all have the same administrable dose form and units of presentation, which are the same for the manufactured items and the pharmaceutical products.

The following information is included in the SmPC of this example:

**Figure 11 - Example of contraceptive medicinal product Qlaira**

### 3.4.1 Representation of Manufactured Items

When a product contains multiple pharmaceutical products, the manufactured items are usually identical to the pharmaceutical products unless the pharmaceutical product is made by combining manufactured items prior to administration. Therefore, ingredient information used for the manufactured item is also used for pharmaceutical product. The ingredients of each manufactured item of a medicinal product must be described and submitted. For reasons of legibility, ingredients details for only one of the manufactured items are shown below.

**Figure 12 - Manufactured Item with multiple Pharmaceutical Products**

A manufactured Item description text can be used to differentiate between manufactured items when necessary. In this example (contraceptive), this includes the colour of each manufactured item.

### 3.4.2 Representation of Pharmaceutical Products

In situations where the medicinal product contains several pharmaceutical products which do not require reconstitution (combining) prior to administration (e.g., powder and solvent), the field "combined pharmaceutical dose form" is not relevant and is left blank.

In this example of contraceptive, a pharmaceutical product section is completed for each "pharmaceutical product" present in the medicinal product, including one for the placebo, as the pharmaceutical products contained in Qlaira do not undergo any transformation before administration. The pharmaceutical section is "repeated".

For each pharmaceutical product section, the administrable dose form, the unit of presentation, the route of administration and the ingredients present in each of the pharmaceutical product is completed.
Note: for reasons of simplicity, not all items are shown in this example.

Figure 13 - Product with multiple Pharmaceutical Products

4 Conclusions

This document describes the minimal attributes needed in a medication list stored in a pharmacy system and their structural relationships required for the unique identification of medicinal products. Data elements that identify and characterise a medicinal product include the product name, the pharmaceutical product (substance, dosage form, route of administration and strength), and the medicinal product packaging.

The PhPID uniquely associates medical products with the same or similar pharmaceutical composition based on the following data elements: substance(s), strength(s) (units of measurement/presentation), reference strength(s), and dosage form.

The benefits of IDMP include:

- Unambiguous global identification and with that will help pharmacists to use medication list information to provide high quality pharmaceutical care.
- Communicate medicinal product data globally.
- Harmonized source for product information based on vocabularies and standards that are consistent across the globe.

IDMP supports the exchange of medicinal product information between pharmacist, patient, and other health care professionals.